GPER-1 acts as a tumor suppressor in ovarian cancer

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Ignatov, Tanja ^a   Modl, Saskia ^a,b   Thulig, Maike ^a   Weißenborn, Christine ^a,b   Treeck, Oliver ^c   Ortmann, Olaf ^c   Zenclussen, A C ^b   Costa, Serban Dan ^a   Kalinski, Thomas ^b   Ignatov, Atanas ^a,c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b University Clinic   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

GPER 1; GPR30; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 2; CYCLIN B1; G PROTEIN COUPLED RECEPTOR 1; G PROTEIN COUPLED RECEPTOR 1 AGONIST; G PROTEIN COUPLED RECEPTOR 30; HISTONE H3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84880110898     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-51     Document Type: Article

References (34)

1. Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Bray F, Loos AH, Tognazzo S, La Vecchia C, Int J Cancer 2005 113 977 990 10.1002/ijc.20649 15505879 (Pubitemid 40096878)
2. Cancer statistics, 2010. Jemal A, Siegel R, Xu J, Ward E, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
3. The biology of ovarian cancer: new opportunities for translation. Bast RC Jr, Hennessy B, Mills GB, Nat Rev Cancer 2009 9 415 428 10.1038/nrc2644 19461667
4. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ, Annu Rev Physiol 2008 70 165 190 10.1146/annurev.physiol.70.113006.100518 18271749 (Pubitemid 351738176)
5. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI, Mol Endocrinol 2002 16 70 84 10.1210/me.16.1.70 11773440 (Pubitemid 34044499)
6. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. Filardo EJ, J Steroid Biochem Mol Biol 2002 80 231 238 10.1016/S0960-0760(01)00190-X 11897506 (Pubitemid 34233742)
7. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Ahola TM, Manninen T, Alkio N, Ylikomi T, Endocrinology 2002 143 3376 3384 10.1210/en.2001-211445 12193550 (Pubitemid 34925712)
8. Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Ahola TM, Alkio N, Manninen T, Ylikomi T, Endocrinology 2002 143 4620 4626 10.1210/en.2002-220492 12446589 (Pubitemid 35397603)
9. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC, Cancer Res 2010 70 1184 1194 10.1158/0008-5472.CAN-09-3068 20086172
10. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM, Cell Death Differ 2010 17 1511 1523 10.1038/cdd.2010.20 20203690
11. GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERalpha) phosphorylation signals. Gao F, Ma X, Ostmann AB, Das SK, Endocrinology 2011 152 1434 1447 10.1210/en.2010-1368
12. GPER-1 Expression Decreases During Breast Cancer Tumorigenesis. Ignatov T, Weissenborn C, Poehlmann A, Lemke A, Semczuk A, Roessner A, Costa SD, Kalinski T, Ignatov A, Cancer Invest 2013 31 309 315 10.3109/07357907.2013. 789901 23688258
13. GPR30 predicts poor survival for ovarian cancer. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER, Gynecol Oncol 2009 114 465 471 19501895
14. The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. Kolkova Z, Casslen V, Henic E, Ahmadi S, Ehinger A, Jirstrom K, Casslen B, J Ovarian Res 2012 5 9 10.1186/1757-2215-5- 9 22424333
15. GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. Fujiwara S, Terai Y, Kawaguchi H, Takai M, Yoo S, Tanaka Y, Tanaka T, Tsunetoh S, Sasaki H, Kanemura M, Tanabe A, Yamashita Y, Ohmichi M, J Ovarian Res 2012 5 35 10.1186/1757-2215-5-35 23163984
16. The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner. Wang C, Lv X, Jiang C, Davis JS, Am J Transl Res 2012 4 390 402 23145207
17. Assessment of response to therapy in advanced breast cancer. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD, Br J Cancer 1977 35 292 298 10.1038/bjc.1977.42 856236
18. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD, Kalinski T, Breast Cancer Res Treat 2011 128 457 466 10.1007/s10549-011-1584-1 21607586
19. Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Ignatov T, Eggemann H, Semczuk A, Smith B, Bischoff J, Roessner A, Costa SD, Kalinski T, Ignatov A, Am J Obstet Gynecol 2010 203 595 16 20965484
20. RANTES stimulates Ca2+ mobilization and inositol trisphosphate (IP3) formation in cells transfected with G protein-coupled receptor 75. Ignatov A, Robert J, Gregory-Evans C, Schaller HC, Br J Pharmacol 2006 149 490 497 10.1038/sj.bjp.0706909 17001303 (Pubitemid 44658509)
21. In vivo effects of a GPR30 antagonist. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER, Nat Chem Biol 2009 5 421 427 10.1038/nchembio.168 19430488
22. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T, Breast Cancer Res Treat 2010 123 87 96 10.1007/s10549-009-0624-6 19911269
23. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr, Mol Endocrinol 2000 14 1649 1660 10.1210/me.14.10.1649 11043579
24. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M, Breast Cancer Res Treat 2010 123 51 58 10.1007/s10549-009-0631- 7 19902352
25. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M, Cancer Res 2007 67 1859 1866 10.1158/0008-5472.CAN-06-2909 17308128 (Pubitemid 46383413)
26. GPER mediates the Egr-1 expression induced by 17beta-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Vivacqua A, Romeo E, De Marco P, De Francesco EM, Abonante S, Maggiolini M, Breast Cancer Res Treat 2012 133 1025 1035 10.1007/s10549-011-1901-8 22147081
27. The GPER1 Agonist G-1 Attenuates Endothelial Cell Proliferation by Inhibiting DNA Synthesis and Accumulating Cells in the S and G2 Phases of the Cell Cycle. Holm A, Baldetorp B, Olde B, Leeb-Lundberg LM, Nilsson BO, J Vasc Res 2011 48 327 335 10.1159/000322578 21273787
28. Role of cyclin B1/Cdc2 up-regulation in the development of mitotic prometaphase arrest in human breast cancer cells treated with nocodazole. Choi HJ, Fukui M, Zhu BT, PLoS One 2011 6 24312 10.1371/journal.pone.0024312
29. Histone H3 phosphorylation and cell division. Hans F, Dimitrov S, Oncogene 2001 20 3021 3027 10.1038/sj.onc.1204326 11420717 (Pubitemid 32553556)
30. An essential role for p73 in regulating mitotic cell death. Toh WH, Nam SY, Sabapathy K, Cell Death Differ 2010 17 787 800 10.1038/cdd.2009.181 20010785
31. Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. Henic E, Noskova V, Hoyer-Hansen G, Hansson S, Casslen B, Int J Gynecol Cancer 2009 19 214 222 10.1111/IGC.0b013e31819bcb75 19395996
32. Functional mechanisms for human tumor suppressors. Sun W, Yang J, J. Cancer 2010 1 136 140 20922055
33. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Liu Q, Li JG, Zheng XY, Jin F, Dong HT, Chin Med J (Engl) 2009 122 2763 2769
34. The Cell Surface Estrogen Receptor, G Protein- Coupled Receptor 30 (GPR30), is Markedly Down Regulated During Breast Tumorigenesis. Poola I, Abraham J, Liu A, Marshalleck JJ, Dewitty RL, Breast Cancer (Auckl.) 2008 1 65 78